A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02438-x ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Medical Oncology, 2024. Verfasst von Mitsuru Okuno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Gifu Municipal Hospital, Japan 7-1 Kashimacho, Gifu City, 500-8513, Japan. mkobdkl@yahoo.co.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Paclitaxel, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX are widely used as first-line regimens for unresectable pancreatic cancer (PC). When GnP therapy is selected, considering patient age or condition, second-line FOLFIRINOX is sometimes difficult to administer owing to its toxicity. This study aimed to determine the recommended dose (RD) of S-IROX (S-1, oxaliplatin, and irinotecan combination) regimens in patients with unresectable PC after first-line GnP failure. This phase-I study used the "3 + 3" dose-escalation design with two dose levels. Patients who failed first-line GnP therapy for unresectable PC were enrolled. Oxaliplatin and irinotecan were administered on day 1, and S-1 was administered orally twice daily on days 1-7, followed by 7 days of rest. The primary endpoints were dose-limiting toxicities (DLTs) and determination of RD. The secondary endpoint was the evaluation of potential antitumor activity. Nine patients received the second-line S-IROX regimen. In level-0 (S-1, 80 mg/m2; oxaliplatin, 85 mg/m2; and irinotecan, 120 mg/m2), no patient experienced DLT; however, one patient experienced grade 3 neutropenia. At level-1 (irinotecan increased to 150 mg/m2), one of six patients experienced DLTs, including G3 diarrhea. The RD was confirmed at the level-1 dose. The response rate, disease control rate, median progression-free survival, and median overall survival were 33.3%, 77.8%, 172 (range:77-422) days, and 414 (101-685) days, respectively. One patient underwent surgery after the second-line S-IROX therapy. Second-line S-IROX treatment was deemed acceptable. The RD was set at level-1 dose (S-1, 80 mg/m2; oxaliplatin, 85 mg/m2; and irinotecan, 150 mg/m2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Gifu Municipal Hospital, Japan 7-1 Kashimacho, Gifu City, 500-8513, Japan. mkobdkl@yahoo.co.jp.
- Department of Gastroenterology, Matsunami General Hospital, Kanazawa, Japan. mkobdkl@yahoo.co.jp.
- Department of Gastroenterology, Gifu Municipal Hospital, Japan 7-1 Kashimacho, Gifu City, 500-8513, Japan.
- Department of Gastroenterological Endoscopy, Kanazawa Medical University, Kanazawa, Japan.
- Department of Gastroenterology, Matsunami General Hospital, Kanazawa, Japan.
Zitieren
APA
Okuno, M., Mukai, T., Iwata, K., Takagi, A., Ito, Y., Ohashi, Y., Tezuka, R., Iwasa, Y., Iwata, S., & Tomita, E. (2024). A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure. Medical Oncology. https://doi.org/10.1007/s12032-024-02438-x
Vancouver
Okuno M, Mukai T, Iwata K, Takagi A, Ito Y, Ohashi Y, et al. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure. Medical Oncology. 2024. doi:10.1007/s12032-024-02438-x
BibTeX
@article{Okuno2024,
author = {Okuno, Mitsuru and Mukai, Tsuyoshi and Iwata, Keisuke and Takagi, Akihiro and Ito, Yuki and Ohashi, Yosuke and Tezuka, Ryuichi and Iwasa, Yuhei and Iwata, Shota and Tomita, Eiichi},
title = {A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02438-x}
}
EUVIMED